3 Clinician Update: Direct Thrombin Inhibitors and Low Molecular Weight Heparins in Acute Coronary Syndromes

2005 ◽  
pp. 521-550
Keyword(s):  
Molecular Weight ◽  
Acute Coronary Syndromes ◽  
Thrombin Inhibitors ◽  
Direct Thrombin Inhibitors ◽  
Low Molecular Weight ◽  
Low Molecular Weight Heparins ◽  
Coronary Syndromes

Parenteral anticoagulants in heart disease: Current status and perspectives (Section II)

2013 ◽  
Vol 109 (05) ◽  
pp. 769-786 ◽  
Author(s):  
Steen Husted ◽  
Lars Wallentin ◽  
Felicita Andreotti ◽  
Harald Arnesen ◽  
Fedor Bachmann ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Heart Disease ◽  
Unfractionated Heparin ◽  
Heart Diseases ◽  
Thrombin Inhibitors ◽  
Current Status ◽  
Direct Thrombin Inhibitors ◽  
Low Molecular Weight ◽  
Low Molecular Weight Heparins ◽  
Ongoing Research

SummaryAnticoagulants are a mainstay of cardiovascular therapy, and parenteral anticoagulants have widespread use in cardiology, especially in acute situations. Parenteral anticoagulants include unfractionated heparin, low-molecular-weight heparins, the synthetic pentasaccharides fondaparinux, idraparinux and idrabiotaparinux, and parenteral direct thrombin inhibitors. The several shortcomings of unfractionated heparin and of low-molecular-weight heparins have prompted the development of the other newer agents. Here we review the mechanisms of action, pharmacological properties and side effects of parenteral anticoagulants used in the management of coronary heart disease treated with or without percutaneous coronary interventions, cardioversion for atrial fibrillation, and prosthetic heart valves and valve repair. Using an evidence-based approach, we describe the results of completed clinical trials, highlight ongoing research with currently available agents, and recommend therapeutic options for specific heart diseases.

Sign in / Sign up

Export Citation Format

Share Document